Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL538614 | 0.99 | SRC (0.60) | SRCRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL27793696 | 0.88 | SMN1; SMN2 (0.53) | SRCRAB9AALDH1A1CNR1KCNQ3 | |
| Hydrochloric Acid SCHEMBL27794148 | 0.87 | SMN1; SMN2 (0.52) | SRCRAB9AALDH1A1CNR1KCNQ3 | |
| SCHEMBL254294 | 0.83 | SRC (0.60) | SRCRAB9AMAPK1GAACNR1 | |
| SCHEMBL254590 | 0.83 | SRC (0.66) | SRCRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL254165 | 0.82 | SRC (0.72) | SRCRAB9AMAPK1ALDH1A1ERCC1 | |
| SCHEMBL254295 | 0.82 | SRC (0.65) | SRCRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL29580134 | 0.79 | SRC (0.61) | SRCRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL254478 | 0.79 | SRC (0.61) | SRCRAB9AMAPK1ALDH1A1GAA | |
| SCHEMBL29580802 | 0.78 | SRC (0.63) | SRCRAB9AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9580387-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-8980890-B2 | Compositions and methods of treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140213587-A1 | Biaryl Compositions and Methods for Modulating a Kinase Cascade | KINEX PHARMACEUTICALS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2008127728-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008002676-A9 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008002676-A2 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1836169-A2 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | Kinex Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2006-07-20 | — | — | US | disclosed |
| WO-2006071960-A2 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | KINEX PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | SRC 116/4885RAB9A 3249/4885MAPK1 171/4885 |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885RAB9A 2334/4885MAPK1 158/4885 |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | MKI67, PCNA, CCAR2 | SRC 3344/4885RAB9A 3352/4885MAPK1 798/4885 |
| US-20140213587-A1 | Biaryl Compositions and Methods for Modulating a Kinase Cascade | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885RAB9A 2334/4885MAPK1 158/4885 |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885RAB9A 2334/4885MAPK1 158/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885RAB9A 2334/4885MAPK1 158/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | SRC 112/4885RAB9A 2244/4885MAPK1 101/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885RAB9A 2334/4885MAPK1 158/4885 |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | MKI67, CCNC, CCNA1 | SRC 430/4885RAB9A 2947/4885MAPK1 920/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | SRC 430/4885RAB9A 2947/4885MAPK1 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.